MMP9 and relapsing-remitting multiple sclerosis: In this respect, it has been demonstrated that IFN-β reduces T-lymphocyte transmigration by interfering with the production of MMP-917 and that the treatment of RRMS patients with IFN-β reduces serum MMP-9 concentrations and ameliorates the course of the disease18.